Developing a Minimally Structured Mathematical Model of Cancer Treatment with Oncolytic Viruses and Dendritic Cell Injections

Mathematical models of biological systems must strike a balance between being sufficiently complex to capture important biological features, while being simple enough that they remain tractable through analysis or simulation. In this work, we rigorously explore how to balance these competing interests when modeling murine melanoma treatment with oncolytic viruses and dendritic cell injections. Previously, we developed a system of six ordinary differential equations containing fourteen parameters that well describes experimental data on the efficacy of these treatments. Here, we explore whether this previously developed model is the minimal model needed to accurately describe the data. Using a variety of techniques, including sensitivity analyses and a parameter sloppiness analysis, we find that our model can be reduced by one variable and three parameters and still give excellent fits to the data. We also argue that our model is not too simple to capture the dynamics of the data, and that the original and minimal models make similar predictions about the efficacy and robustness of protocols not considered in experiments. Reducing the model to its minimal form allows us to increase the tractability of the system in the face of parametric uncertainty.

[1]  Hoguen Kim,et al.  Therapeutic and Tumor-specific Immunity Induced by Combination of Dendritic Cells and Oncolytic Adenovirus Expressing IL-12 and 4-1BBL , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[2]  F. Emmert-Streib Personalized medicine: Has it started yet? A reconstruction of the early history , 2013, Front. Genet..

[3]  Eduardo D Sontag,et al.  Evaluating optimal therapy robustness by virtual expansion of a sample population, with a case study in cancer immunotherapy , 2017, Proceedings of the National Academy of Sciences.

[4]  Manuel Arruebo,et al.  Assessment of the Evolution of Cancer Treatment Therapies , 2011, Cancers.

[5]  I. Sobola,et al.  Global sensitivity indices for nonlinear mathematical models and their Monte Carlo estimates , 2001 .

[6]  J. Blay,et al.  Personalized medicine in oncology: where have we come from and where are we going? , 2013, Pharmacogenomics.

[7]  M. Verma Personalized Medicine and Cancer , 2012, Journal of personalized medicine.

[8]  Nicholas R. Lemoine,et al.  Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles , 2010, Viruses.

[9]  J. Gunawardena Models in Systems Biology: The Parameter Problem and the Meanings of Robustness , 2010 .

[10]  R. Coffey,et al.  Volume of Preclinical Xenograft Tumors Is More Accurately Assessed by Ultrasound Imaging Than Manual Caliper Measurements , 2010, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

[11]  Joanna R. Wares,et al.  Treatment strategies for combining immunostimulatory oncolytic virus therapeutics with dendritic cell injections. , 2015, Mathematical biosciences and engineering : MBE.

[12]  H. Akaike,et al.  Information Theory and an Extension of the Maximum Likelihood Principle , 1973 .

[13]  G. Schwarz Estimating the Dimension of a Model , 1978 .

[14]  Adelle C F Coster,et al.  Mathematical Modelling of the Interaction Between Cancer Cells and an Oncolytic Virus: Insights into the Effects of Treatment Protocols , 2018, Bulletin of mathematical biology.

[15]  Raluca Eftimie,et al.  Tumour-associated macrophages and oncolytic virotherapies: a mathematical investigation into a complex dynamics , 2018 .

[16]  Yuri Kogan,et al.  Predicting Outcomes of Prostate Cancer Immunotherapy by Personalized Mathematical Models , 2010, PloS one.

[17]  P. Fisher,et al.  Gene Therapies for Cancer: Strategies, Challenges and Successes , 2015, Journal of cellular physiology.

[18]  Hulin Wu,et al.  Differential Equation Modeling of HIV Viral Fitness Experiments: Model Identification, Model Selection, and Multimodel Inference , 2009, Biometrics.

[19]  Mads Kærn,et al.  Model-based rational design of an oncolytic virus with improved therapeutic potential , 2013, Nature Communications.

[20]  M. Goulian,et al.  Robustness and the cycle of phosphorylation and dephosphorylation in a two-component regulatory system , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[21]  S. Leibler,et al.  Robustness in simple biochemical networks , 1997, Nature.

[22]  Hoguen Kim,et al.  Therapeutic and Tumor-specific Immunity Induced by Combination of Dendritic Cells and Oncolytic Adenovirus Expressing IL-12 and 4-1BBL. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[23]  L. G. Pillis,et al.  A Comparison and Catalog of Intrinsic Tumor Growth Models , 2013, Bulletin of mathematical biology.

[24]  Dominik Wodarz,et al.  Towards Predictive Computational Models of Oncolytic Virus Therapy: Basis for Experimental Validation and Model Selection , 2009, PloS one.

[25]  K. S. Brown,et al.  Statistical mechanical approaches to models with many poorly known parameters. , 2003, Physical review. E, Statistical, nonlinear, and soft matter physics.

[26]  H. Enderling,et al.  Fighting Cancer with Mathematics and Viruses , 2017, Viruses.

[27]  C. Figdor,et al.  Dendritic Cell–Based Immunotherapy: State of the Art and Beyond , 2016, Clinical Cancer Research.

[28]  David Hinkley,et al.  Bootstrap Methods: Another Look at the Jackknife , 2008 .

[29]  Jeremy Gunawardena,et al.  Programming with models: modularity and abstraction provide powerful capabilities for systems biology , 2009, Journal of The Royal Society Interface.

[30]  Christopher R. Myers,et al.  Universally Sloppy Parameter Sensitivities in Systems Biology Models , 2007, PLoS Comput. Biol..

[31]  Dominik Wodarz,et al.  ODE models for oncolytic virus dynamics. , 2010, Journal of theoretical biology.

[32]  Joanna R. Wares,et al.  Quantitative impact of immunomodulation versus oncolysis with cytokine-expressing virus therapeutics. , 2015, Mathematical biosciences and engineering : MBE.

[33]  G. Trinchieri,et al.  Interleukin-12 in anti-tumor immunity and immunotherapy. , 2002, Cytokine & growth factor reviews.

[34]  Charles Swanton,et al.  Translational Implications of Tumor Heterogeneity , 2015, Clinical Cancer Research.

[35]  Clifford M. Hurvich,et al.  Regression and time series model selection in small samples , 1989 .

[36]  J. Feldman A MATHEMATICAL MODEL FOR TUMOR VOLUME EVALUATION USING TWO-DIMENSIONS , 2010 .

[37]  T. Watts,et al.  4-1BB Ligand-Mediated Costimulation of Human T Cells Induces CD4 and CD8 T Cell Expansion, Cytokine Production, and the Development of Cytolytic Effector Function1 , 2002, The Journal of Immunology.

[38]  Flavio Cannavó,et al.  Sensitivity analysis for volcanic source modeling quality assessment and model selection , 2012, Comput. Geosci..

[39]  K. J. Mahasa,et al.  Oncolytic potency and reduced virus tumor-specificity in oncolytic virotherapy. A mathematical modelling approach , 2017, PloS one.

[40]  B. Efron Bootstrap Methods: Another Look at the Jackknife , 1979 .

[41]  T. Bekaii-Saab,et al.  The Continued Promise and Many Disappointments of Oncolytic Virotherapy in Gastrointestinal Malignancies , 2017, Biomedicines.

[42]  Seth Sullivant,et al.  Identifiability Results for Several Classes of Linear Compartment Models , 2014, Bulletin of Mathematical Biology.

[43]  L. Aurelian Oncolytic viruses as immunotherapy: progress and remaining challenges , 2016, OncoTargets and therapy.